You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 2. A bibliometric analysis of liver cancer bone metastases: advances in mechanisms of occurrence and treatment options
- 3. Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
- 4. BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient
- 5. Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer
- 6. Radiopharma's new wave: Nuclidium and Actithera raise the stakes
- 7. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 8. ESCO2 inhibition induces cell cycle arrest and apoptosis in breast cancer via the P53-CDK1 axis and the BAX/Bcl2/caspase signaling cascade
- 9. Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- 10. Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer
Last updated at 7:43 GMT
Hot News Makers
Health/Pharma Companies
-
20520.67
-
8819.20
-
7559.32
-
6978.67
-
3838.09
-
3548.91
-
2158.98
-
2096.76
-
1837.14
-
1701.68
Drugs, Treatments, Trials
-
20796.12
-
5967.91
-
3558.60
-
2131.40
-
1936.70
-
1356.34
-
1001.41
-
820.54
-
568.07
-
487.33
Last updated at 7:10 GMT
